The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Characterizing the development of MDS in patients with CLL in the era of targeted therapies
Adam Kittai, MD, Ohio State University, Columbus, OH, comments on the importance of better understanding how patients with chronic lymphocytic leukemia (CLL) may develop secondary myelodysplastic syndromes (MDS) in the era of novel therapies including Bcl-2 and BTK inhibitors, highlighting the impact of high-risk mutations and briefly discussing the management of these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy; Astrazeneca: Consultancy, Research Funding; Beigene: Consultancy; Janssen: Consultancy.
